|
|
|
FDA Home Page | Search FDA Site | A-Z Index | Contact FDA
|
FOR IMMEDIATE RELEASE |
Media Inquiries: 301-827-6242 |
The Food and Drug Administration (FDA) today informed CanaRx Services, Inc. (CanaRx), the business supplying prescription drugs to the City of Springfield, Mass., that its operations are illegal under federal law and that it continues to put American patients at risk by providing them with unapproved, illegal, and potentially risky foreign prescription drugs.
These conclusions came in FDA’s formal reply to a letter from CanaRx in which the firm outlined certain operational changes it made following receipt of a warning letter from FDA last September. (The warning letter is available online at http://www.fda.gov/bbs/topics/NEWS/2003/NEW00946.html.
Today’s letter reiterates FDA’s serious safety concerns about
the business practices and continuing illegal actions that may put the firm’s
customers at risk.
Specifically, FDA’s letter to the firm finds that:
“The drug safety laws that Congress has charged FDA to enforce require that drugs be proven to be safe and effective to be legal,” said Commissioner of Food and Drugs Mark B. McClellan, M.D., Ph.D. “While FDA will continue to do all it can to make safe and affordable drugs available, we are also committed to enforcing the law against those, whether governmental or private, who endanger Americans by profiting from ‘buyer beware’ schemes to import illegal, unapproved and potentially risky medicines.”
FDA has long been concerned that medications purchased by U.S. consumers from foreign, unregulated drug outlets pose a growing potential danger. CanaRx and similar companies often state incorrectly to consumers that their products are "FDA approved" or use similar language, which could lead consumers to conclude mistakenly that the prescription drugs sold by the companies have the same assurance of safety and effectiveness as drugs regulated by the FDA. They do not.
The medications obtained and shipped by operations such as CanaRx are not subject to FDA’s safety oversight. This gap prevents assurance that CanaRx’s medications are safe and effective, are prescribed and distributed properly, and otherwise meet U.S. prescription drug standards. In this case, these risks are heightened by the fact that many of the products CanaRx sells to U.S. consumers are indicated for serious medical conditions.
In addition, foreign dispensers of drugs to American consumers may provide patients with incorrect medications, drugs with incorrect strengths, medicines that should not be used by people with certain conditions or with other medications, or medications without proper directions for use.
For example, of the 1,153 imported drug products examined during a recent “blitz” by FDA and the Bureau of Customs and Border Protection, the overwhelming majority, 1,019 (88%), were illegal because they contained unapproved drugs. Many of these imported drugs could pose clear safety risks to consumers. These drugs arrived from many countries, with 15.8% (161) entering the U.S. from Canada.
Finally, there are no reliable methods to detect adverse events caused by
drugs supplied by firms like CanaRx, or to take action against the company
when adverse events occur. In fact, companies like CanaRx routinely state
that they have no liability or responsibility for adverse consequences
of the drugs they provide.
Although many legitimate domestic Internet pharmacies provide safe and possibly
more convenient access to prescription services, foreign Internet pharmacies
selling unapproved foreign drugs to the U.S. operate outside the law. FDA
provides guidance to consumers on buying prescription drugs safely over the
Internet at http://www.fda.gov/oc/buyonline/default.htm.
FDA Letter to CanaRx Services, Inc., Nov. 6, 2003
###